1
|
Su J, Liu Y, Sun H, Naeem A, Xu H, Qu Y, Wang C, Li Z, Lu J, Wang L, Wang X, Wu J, Sun L, Zhang J, Wang Z, Yang R, Wu L. Visualization of nasal powder distribution using biomimetic human nasal cavity model. Acta Pharm Sin B 2024; 14:392-404. [PMID: 38261815 PMCID: PMC10792963 DOI: 10.1016/j.apsb.2023.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 05/09/2023] [Accepted: 05/19/2023] [Indexed: 01/25/2024] Open
Abstract
Nasal drug delivery efficiency is highly dependent on the position in which the drug is deposited in the nasal cavity. However, no reliable method is currently available to assess its impact on delivery performance. In this study, a biomimetic nasal model based on three-dimensional (3D) reconstruction and three-dimensional printing (3DP) technology was developed for visualizing the deposition of drug powders in the nasal cavity. The results showed significant differences in cavity area and volume and powder distribution in the anterior part of the biomimetic nasal model of Chinese males and females. The nasal cavity model was modified with dimethicone and validated to be suitable for the deposition test. The experimental device produced the most satisfactory results with five spray times. Furthermore, particle sizes and spray angles were found to significantly affect the experimental device's performance and alter drug distribution, respectively. Additionally, mometasone furoate (MF) nasal spray (NS) distribution patterns were investigated in a goat nasal cavity model and three male goat noses, confirming the in vitro and in vivo correlation. In conclusion, the developed human nasal structure biomimetic device has the potential to be a valuable tool for assessing nasal drug delivery system deposition and distribution.
Collapse
Affiliation(s)
- Jiawen Su
- Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004, China
- Yangtze Delta Drug Advanced Research Institute, Nantong 226126, China
| | - Yan Liu
- Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Hongyu Sun
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China
| | - Abid Naeem
- Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004, China
| | - Huipeng Xu
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China
| | - Yue Qu
- Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Caifen Wang
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China
- Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Zeru Li
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China
- Nanjing University of Chinese Medicine, Nanjing 210023, China
| | - Jianhua Lu
- Nantong Haimen People's Hospital, Nantong 226199, China
| | - Lulu Wang
- National Institutes for Food and Drug Control, Beijing 100000, China
| | - Xiaofeng Wang
- National Institutes for Food and Drug Control, Beijing 100000, China
| | - Jie Wu
- Nantong Haimen People's Hospital, Nantong 226199, China
- Yangtze Delta Drug Advanced Research Institute, Nantong 226126, China
| | - Lixin Sun
- Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Jiwen Zhang
- Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004, China
- Key Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Yantai University, Yantai 264005, China
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China
- Yangtze Delta Drug Advanced Research Institute, Nantong 226126, China
| | - Zhigang Wang
- Nantong Haimen People's Hospital, Nantong 226199, China
| | - Rui Yang
- Shenyang Pharmaceutical University, Shenyang 110016, China
- National Institutes for Food and Drug Control, Beijing 100000, China
| | - Li Wu
- Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004, China
- Key Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Yantai University, Yantai 264005, China
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China
- Yangtze Delta Drug Advanced Research Institute, Nantong 226126, China
| |
Collapse
|
2
|
Mayor A, Thibert B, Huille S, Bensaid F, Respaud R, Audat H, Heuzé-Vourc'h N. Inhaled IgG1 antibodies: The buffering system is an important driver of stability during mesh-nebulization. Eur J Pharm Biopharm 2022; 181:173-182. [PMID: 36395981 DOI: 10.1016/j.ejpb.2022.11.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 11/09/2022] [Accepted: 11/10/2022] [Indexed: 11/16/2022]
Abstract
In the past decade, oral inhalation has been a thriving focus of research to administer antibody directly to the lungs as an aerosol, for local treatment of respiratory diseases. Formulation of inhaled antibodies is central for the stability of antibody, lung safety and to ensure inhaler performances. Surfactants have already been shown to prevent antibody degradation during aerosolization, but little is known about the impact of other components of liquid formulations on the structural stability of antibodies. Here, we report for the first time to the best of our knowledge, a significant effect of the buffering system on monoclonal antibodies stability, during mesh-nebulization. While the monoclonal antibody extensively aggregated in citrate buffer after nebulization and required high concentration of polysorbate 80 (PS80) to maintain protein integrity, acetate and histidine buffers resulted in a slight to moderate aggregation without PS80 and low concentration of PS80 was sufficient to stabilize antibody during mesh-nebulization.
Collapse
Affiliation(s)
- Alexie Mayor
- INSERM, Centre D'Etude Des Pathologies Respiratoires, Université François Rabelais de Tours, 10 Boulevard Tonnellé, U1100F-37032 Tours, France; University of Tours, Tours, France; Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400 Vitry-sur-Seine, France
| | - Béatrice Thibert
- Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400 Vitry-sur-Seine, France
| | - Sylvain Huille
- Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400 Vitry-sur-Seine, France
| | - Fethi Bensaid
- Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400 Vitry-sur-Seine, France
| | - Renaud Respaud
- INSERM, Centre D'Etude Des Pathologies Respiratoires, Université François Rabelais de Tours, 10 Boulevard Tonnellé, U1100F-37032 Tours, France
| | - Héloïse Audat
- Sanofi, Formulation and Process Development, Impasse Des Ateliers, 94400 Vitry-sur-Seine, France
| | - Nathalie Heuzé-Vourc'h
- INSERM, Centre D'Etude Des Pathologies Respiratoires, Université François Rabelais de Tours, 10 Boulevard Tonnellé, U1100F-37032 Tours, France; University of Tours, Tours, France.
| |
Collapse
|